Manulife (Manufacturers Life Insurance)
RAPP

Manulife (Manufacturers Life Insurance)’s Rapport Therapeutics RAPP Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.36M Sell
75,359
-3,300
-4% -$92.8K ﹤0.01% 1436
2025
Q4 		$2.41M Sell
78,659
-3,672
-4% -$102K ﹤0.01% 1449
2025
Q3 		$2.45M Sell
82,331
-18,093
-18% -$323K ﹤0.01% 1443
2025
Q2 		$1.14M Buy
100,424
+21,493
+27% +$228K ﹤0.01% 1760
2025
Q1 		$792K Buy
78,931
+1,656
+2% +$21.5K ﹤0.01% 1917
2024
Q4 		$1.37M Sell
77,275
-69
-0.1% -$1.53K ﹤0.01% 1750
2024
Q3 		$1.58M Buy
77,344
+1,828
+2% +$39.3K ﹤0.01% 1674
2024
Q2 		$1.76M Buy
+75,516
New +$1.75M ﹤0.01% 1540

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s RAPP Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Rapport Therapeutics (RAPP) stake by 4.2% in Q1 2026, selling an estimated $92.8K and leaving 75,359 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1436.

Manulife (Manufacturers Life Insurance) first reported a position in RAPP in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.45M in Q3 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 75,359 shares of Rapport Therapeutics worth $2.36M as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 3,300 Rapport Therapeutics shares in Q1 2026, an estimated $92.8K.
  • Rapport Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1436 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Rapport Therapeutics position peaked at $2.45M in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.